Tsang, John S.

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science

interferon and immune responsesSARS-CoV-2 and COVID-19 Research

Cited by 2,662

MicroRNA-Mediated Feedback and Feedforward Loops Are Recurrent Network Motifs in Mammals

Tsang, J., Zhu, J., & van Oudenaarden, A. (2007) · Molecular Cell

MicroRNA in disease regulationGene Regulatory Network Analysis

Cited by 740

Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19

Sacco, K., Castagnoli, R., Vakkilainen, S., Liu, C., Delmonte, O. M., Oguz, C., Kaplan, I. M., Alehashemi, S., Burbelo, P. D., Bhuyan, F., et al. (2022) · Nature Medicine

Kawasaki Disease and Coronary ComplicationsCOVID-19 Clinical Research Studies

Cited by 247

Normalizing and denoising protein expression data from droplet-based single cell profiling

Mulè, M. P., Martins, A. J., & Tsang, J. S. (2022) · Nature Communications

Single-cell and spatial transcriptomicsGene expression and cancer classification

Cited by 197

Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes

Lledó-Delgado, A., Preston-Hurlburt, P., Currie, S., Clark, P., Linsley, P. S., Long, S. A., Liu, C., Koroleva, G., Martins, A. J., Tsang, J. S., et al. (2024) · Journal of Clinical Investigation

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 58

Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

Khurana, S., King, L. R., Manischewitz, J., Posadas, O., Mishra, A. K., Liu, D., Beigel, J. H., Rappuoli, R., Tsang, J. S., & Golding, H. (2024) · Nature Medicine

Influenza Virus Research StudiesVirology and Viral Diseases

Cited by 57